Skip to main content
letter
. 2018 Jul;103(7):e307–e310. doi: 10.3324/haematol.2017.186908

Figure 1.

Figure 1.

Box plots presenting the distribution of serum IgM and hemoglobin levels at the start and the end of ibrutinib hold, in patients with Waldenstrom macroglobulinemia who experienced withdrawal symptoms while holding ibrutinib. Figures 1A and 1B present the distribution in all patients, Figures 1C and 1D in patients who progressed during ibrutinib hold, and Figures 1E and 1F in patients who did not progress during ibrutinib hold.